Vimarsana
Biggest News Aggregation in the World

Page 24 - Multiple System Atrophy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multiple System Atrophy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multiple System Atrophy Today - Breaking & Trending Today

Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy - Vimarsana News

Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that the US Food and Drug Administration...

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023 - Vimarsana News

Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023

BOSTON and ATLANTA, May 8, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of... | May 8, 2023

Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference - Vimarsana News

Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference

/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase...

Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease - Vimarsana News

Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease

/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase...

Gareth O'Callaghan returns home after six weeks in hospital following serious car crash in Cork - Vimarsana News

Gareth O'Callaghan returns home after six weeks in hospital following serious car crash in Cork

Mr O'Callaghan was being treated at Cork University Hospital (CUH) since the incident but was recently transferred to South Infirmary Victoria ...